Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus
Open Access
- 1 August 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (8) , 3256-3263
- https://doi.org/10.1128/aac.49.8.3256-3263.2005
Abstract
Lysostaphin is an endopeptidase that cleaves the pentaglycine cross-bridges of the staphylococcal cell wall rapidly lysing the bacteria. Recently, lysostaphin has been examined for its potential to treat infections and to clear Staphylococcus aureus nasal colonization, requiring a reliable method for determining the lysostaphin susceptibility of strains of S. aureus. We compared four methods for determining the lysostaphin susceptibility of 57 strains of methicillin-sensitive S. aureus, methicillin-resistant S. aureus, vancomycin intermediately susceptible S. aureus (VISA), mupirocin-resistant S. aureus, and various defined genetic mutants of S. aureus. Three reference lysostaphin-resistant S. aureus variants were also included in the assays as negative controls. The assays examined included turbidity, MIC, minimum bactericidal concentration (MBC), and disk diffusion assays. All of the strains of S. aureus tested, including a VISA strain which had previously been reported to be lysostaphin resistant, were susceptible to lysostaphin by all four methods. The three reference lysostaphin-resistant variants were resistant by all four methods. The disk diffusion assay was the simplest method to differentiate lysostaphin-susceptible S. aureus strains from lysostaphin-resistant variants, while the MBC assay could be used as a follow-up assay if required. In the disk diffusion assay, all strains of S. aureus tested revealed zones of inhibition of ≥11 mm using a 50-μg lysostaphin disk, while the three reference lysostaphin-resistant S. aureus variants had no zones of inhibition. In MBC assays, concentrations of lysostaphin ranging from 0.16 μg/ml to 2.5 μg/ml were found to cause a 3 log or greater drop from the initial CFU of S. aureus within 30 min for all strains tested.Keywords
This publication has 46 references indexed in Scilit:
- Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2004
- Staphylococcus aureusCapsular PolysaccharidesClinical Microbiology Reviews, 2004
- In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and BloodAntimicrobial Agents and Chemotherapy, 2003
- Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patientsThe Lancet, 2002
- Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-ResistantStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2001
- Staphylococcus aureus with Reduced Susceptibility to Vancomycin Isolated from a Patient with Fatal BacteremiaEmerging Infectious Diseases, 1999
- Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticusMolecular Microbiology, 1997
- Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semi-synthetic mediumJournal of General Microbiology, 1991
- THERAPEUTIC ACTIVITY OF LYSOSTAPHIN IN EXPERIMENTAL STAPHYLOCOCCAL INFECTIONSCanadian Journal of Microbiology, 1967
- Lysostaphin: Enzymatic mode of actionBiochemical and Biophysical Research Communications, 1965